Objective: To assess the efficiency of the carbon nanoparticles (CNs) in lymph node identification 11 and parathyroid gland protection during thyroidectomy. 12 Methods: A systematic literature search for relevant literatures published up to December 2018 in 13 PubMed, Embase, Web of Science and Cochrane Library was performed. Both English and Chinese 14 literatures were retrieved and analyzed. Randomized controlled trials or nonrandomized controlled 15 trials on the use of CNs during thyroidectomy were enrolled in this study. The primary outcomes 16 included the number of lymph nodes harvesed, rate of lymph nodes involvement, and the rates of 17 accidental parathyroidectomy, hypoparathyroidism, and hypocalcemia. Weighted mean differences 18 (WMDs), odds ratios (ORs) and risk differences (RDs) were calculated for the dichotomous 19 outcome variables. Between-study heterogeneity was tested using the Q tests and the I 2 statistics.
control groups (WMD, 2.36; 95% CI, 1.40 to 3.32; P ＜0.01). Administrating carbon nanoparticles 24 was associated with a lower incidence of accidental parathyroid gland removal (OR = 0.30, 95% CI 25 = 0.23 to 0.40, P ＜0.01) and lower rates of both postoperative transient hypoparathyroidism (OR 26 =0.46, 95% CI = 0.33 to 0.64, P ＜0.01) and transient hypocalcemia (OR =0.55, 95% CI = 0.09 to 27 3.43, P =0.52). There was no significant difference of identified lymph node metastatic rates 28 between the patients with and without use of carbon nanoparticles. Subgroup analyses indicated that 29 the application of CNs in thyroid cancer reoperation also decreased the rate of transient 30 hypoparathyroidism(OR =0.20, 95% CI = 0.36 to 0.04, P =0.01)and the possibility of accidental 31 parathyroid glands removal (OR = 0.19, 95% CI = 0.05 to 0.73, P＜0.05).
Introduction 37
Thyroid cancer is one of the most common types of cancer in the world, the incidence of which 38 increased dramatically in recent two decades(1). Cervical lymph node metastases are common in 39 patients with papillary thyroid carcinoma (PTC), the most common subtype of thyroid cancer(1).
40
Total thyroidectomy combined with levelⅡ-Ⅵ neck dissection for clinically N1b cases or central 41 compartmental dissection (CND) for cN0 case is widely advocated as one of the standard treatment 42 protocols for thyroid cancer, whereas lobectomy is only accepted for T1 cases without high risk 43 factors(2-4). However, it's a challenge for a surgeon to perform a total thyroidectomy plus CND 44 due to the potential risk of postoperative hypocalcemia or hypoparathyroidism, whose incidence 45 ranges from20% to 60% based on the previous reports and even higher for those who undergo a re-46 operation (5, 6) .
47
Carbon nanoparticles (CNs) have been successfully used for sentinel lymph node detection in breast 48 carcinoma, gastric carcinoma, and etc. (7, 8) . The CNs, with a diameter of 150 nm, can easily be 49 captured by macrophages and penetrate the lymphatic capillaries with an endothelial cell gap of 50 20-50 nm rather than the capillary vessels whose endothelial cell gap is 120-500 nm, and they 51 ultimately accumulate in the sentinel lymph nodes. This is the hypothetic basis that CNs can be used 52 as a tracer to detect the sentinel node. In the past decade, CNs had been successfully attempted as a 53 negative developer to protect parathyroid gland during initial thyroidectomy (9). Although a couple 54 of meta-analyses had been published on evaluating the value of CNs in initial thyroid surgery, the 55 data need to be updated (10, 11) . Furthermore, there are still doubts about the efficiency of CNs in 56 re-operation thyroidectomy due to the hypothesis that the lymphatic capillaries may be destroyed 57 during initial surgery (12, 13) . Therefore, we performed a meta-analysis with more comprehensive 4 58 and updated studies to summarize the role of application of CNs in lymph node detection and 59 parathyroid gland protection during both initial and completion thyroidectomy.
60

Materials and Methods
61
Search strategy 
87
Quality Assessment
88
Concerning the quality of study design, the RCT was assessed according to the Jadad scoring system, 89 which consists of 3 items: randomization (0-2 points), blinding (0-2 points), and descriptions of the 90 withdrawals and dropouts (0 or 1 point). The total possible score was 5 points. With regard to 91 NRCTs, the Newcastle-Ottawa Scale was used.
92
Statistical Analysis
93
All analyses with their 95% confidence intervals (95% CIs) were performed in the current meta- 
113
The quality assessment details for the RCTs and NRCTs are presented in Tables 2 and 3 .
114
Surgical procedure
115
The CNs were provided by Chongqing LUMMY Pharmaceutical Co., Ltd. The details of the 116 injection method are shown in Table 4 . In most of the studies, the CN injected underneath the fibrous 117 thyroid capsules at two or three points around the neoplasm, 0.1-0.2ml for each point. And 5-10mins
118 later thyroidectomy or lobectomy and neck dissection were performed.
119
Lymph node removal 120 All studies regarding lymph node dissection are showed in Figure 2 . The total number of lymph 121 node(LN) harvested in the CN group was significant higher than that in the control groups (WMD, 122 2.36; 95% CI, 1.40 to 3.32; P＜0.01, Figure 2 ). There was no difference in total metastatic rate 123 between the two groups (OR = 1.07, 95% CI = 0.75 to 1.57, P=0.71, Figure 3 ). The rate of LN black-7 124 staining varied between 73.3% and 95.3%.
125
Parathyroid gland protection 126
The possibility of accidental parathyroid glands (PGs) removal was decreased by 30% in CN group 127 compared with control group (OR = 0.30, 95% CI = 0.23 to 0.40, P＜ 0.01, Figure 4 ). The 128 application of CN decreased the rate of postoperative transient hypoparathyroidism and transient 129 hypocalcemia by 46% (OR =0.46, 95% CI = 0.33 to 0.64, P＜0.01, Figure 5a ) and 46%(OR 130 =0.46, 95% CI = 0.33 to 0.65, P ＜ 0.01, Figure 5b ), respectively. The Number of postoperative 131 permanent hypocalcemia in CNs group and control group were 1 and 5, respectively(OR =0.55, 95%
132 CI = 0.09 to 3.43, P =0.52, Figure 5c ).
133
CNs application during reoperation 134
For the subgroup of reoperation, CNs significantly decreased the rate of postoperative transient 135 hypoparathyroidism by 21% ( OR =0.20, 95% CI = 0.04 to 0.36, P =0.01, Figure 6 ). The possibility 136 of accidental PGs removal was decreased by 19% in CNs group compared with control group during 137 reoperation (OR = 0.19, 95% CI = 0.05 to 0.73, P＜0.05, Figure 7 ).
138
Discussion 139 Thyroid cancer is one of the most common types of cancer in the world, with a rapid increasing 140 incidence in recent two decades (1) 
171
Hypoparathyroidism is a common complication after thyroid cancer surgery, especially reoperation.
172
The incidence of transient hypoparathyroidism after surgery is reported to be 20% to 60%, while 173 that of permanent hypoparathyroidism is 0% to 7%(5, 6). Our study revealed that application of 174 CNs during lobectomy or CND reduce the rate of PGs accidental removal by approximately 30%.
175
But there were still doubts about practicability for parathyroid protection during thyroid surgery.
176
Liu and Shen reported that CNs play important role in identifying and preserving PGs, but not 177 beneficial for protecting the function of parathyroid gland in thyroid surgery (12, 13) . Further 
187
The current meta-analysis has some limitations and the results should be interpreted with caution.
188
First, all of studies including in this meta-analysis were performed only in 
